EUVIMEDEUVIMED entdecken
Fallbericht

Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series

Koki Sakaguchi, Tatsunori Satoh, Shinya Kawaguchi, Takuya Aoyama, Kazuhisa Asahara, Shinya Endo, Naofumi Shirane, Hideyuki Kanemoto, Noriyuki Oba, Kazuya Ohno

Clinical Journal of Gastroenterology · 2024

DOI: 10.1007/s12328-024-01946-7 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Journal of Gastroenterology, 2024. Verfasst von Koki Sakaguchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shizuoka General Hospital, 4-27-1 Kita Ando, Aoi-Ku, Shizuoka City, Shizuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized, Bevacizumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Three patients aged 79, 75, and 81 years with unresectable hepatocellular carcinoma (HCC) and undergoing maintenance hemodialysis were treated with a combination of atezolizumab and bevacizumab. The patients, respectively, received their 22nd, 2nd, and 4th treatment cycles, and one achieved long-term stable disease. No serious adverse events, including immune-related adverse events, were observed in any patient. Remarkable progress has been made in chemotherapy for cancer; however, the efficacy and safety of chemotherapy in patients undergoing hemodialysis have not been adequately elucidated. This report provides novel insights into the feasibility and outcomes of atezolizumab and bevacizumab combination therapy in patients with HCC undergoing hemodialysis, highlighting its potential as a viable treatment option with manageable side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntibodies, Monoclonal, HumanizedBevacizumabRenal DialysisAntineoplastic Combined Chemotherapy ProtocolsHumansAgedMaleAged, 80 and overFemaleTreatment Outcome

Stichwörter der Autor:innen

ChemotherapyHemodialysisHepatocellular carcinomaIrAE

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedBevacizumab

Autor:innen und Institutionen

  • Department of Gastroenterology, Shizuoka General Hospital, 4-27-1 Kita Ando, Aoi-Ku, Shizuoka City, Shizuoka, Japan.
  • Department of Gastroenterology, Shizuoka General Hospital, 4-27-1 Kita Ando, Aoi-Ku, Shizuoka City, Shizuoka, Japan. tatsunori-sato@i.shizuoka-pho.jp.
  • Department of Gastroenterology, Yaizu City Hospital, Shizuoka, Japan.
  • Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Department of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan.

Zitieren

APA

Sakaguchi, K., Satoh, T., Kawaguchi, S., Aoyama, T., Asahara, K., Endo, S., Shirane, N., Kanemoto, H., Oba, N., & Ohno, K. (2024). Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-024-01946-7

Vancouver

Sakaguchi K, Satoh T, Kawaguchi S, Aoyama T, Asahara K, Endo S, et al. Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series. Clinical Journal of Gastroenterology. 2024. doi:10.1007/s12328-024-01946-7

BibTeX
@article{Sakaguchi2024,
  author = {Sakaguchi, Koki and Satoh, Tatsunori and Kawaguchi, Shinya and Aoyama, Takuya and Asahara, Kazuhisa and Endo, Shinya and Shirane, Naofumi and Kanemoto, Hideyuki and Oba, Noriyuki and Ohno, Kazuya},
  title = {Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series},
  journal = {Clinical Journal of Gastroenterology},
  year = {2024},
  doi = {10.1007/s12328-024-01946-7}
}
Kostenlos starten →